All News


All series


All All News

Join us on Tuesday, April 10 at 1 p.m. EST for our monthly #CureConnect tweet chat, where we’ll focus on our recent gastrointestinal cancers special issue.

The Food and Drug Administration (FDA) granted duvelisib a priority review to a new drug application (NDA) for full approval to treat patients who have relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia (CLL/SLL). The FDA also granted an accelerated approval for the treatment of patients with relapsed or refractory follicular lymphoma.

The Food and Drug Administration (FDA) approved Rubraca (rucaparib) as a maintenance therapy for women with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy, according to Clovis Oncology, the company that manufactures the drug.

After extensive chemo treatment was completed, intended to kill all the leukemic cells in my sick body, a courier was sent to Israel to collect the harvested marrow from my donor, and immediately fly it back to the U.S. where I was to be infused.